

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/19, C07K 14/715, A61K 38/17, C07K 16/18, C12N 15/62		A1	(11) International Publication Number: WO 98/31811
			(43) International Publication Date: 23 July 1998 (23.07.98)
(21) International Application Number: PCT/US98/00334 (22) International Filing Date: 15 January 1998 (15.01.98) (30) Priority Data: 08/784,863 16 January 1997 (16.01.97) US (71) Applicant (for all designated States except US): GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DONALDSON, Debra, D. [US/US]; 108 Blakely Road, Medford, MA 02155 (US). COLLINS, Mary [US/US]; 27 Euclid Avenue, Natick, MA 01760 (US). NEBEN, Tamlyn [US/US]; 13 Duggan Road, Acton, MA 01720 (US). WHITTERS, Matthew [US/US]; 9 Vinal Street, Hudson, MA 01749 (US). (74) Agent: BROWN, Scott, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: MEMBER OF THE HEMATOPOIETIN RECEPTOR SUPERFAMILY			
(57) Abstract Polynucleotides encoding the U4 hematopoietin receptor superfamily chain and fragments thereof are disclosed. U4 proteins and methods for their production are also disclosed.			
A8 - 09/825,561			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

MEMBER OF THE HEMATOPOIETIN RECEPTOR SUPERFAMILY

Field of the Invention

5 The present invention relates to new members of the mammalian hematopoietin superfamily of proteins (including without limitation human and murine receptor proteins), fragments thereof and recombinant polynucleotides and cells useful for expressing such proteins.

10 Background of the Invention

A variety of regulatory molecules, known as hematopoietins, have been identified which are involved in the development and proliferation of the various populations of hematopoietic or blood cells. Most hematopoietins exhibits certain biological activities by interacting with a receptor on the surface of target cells.

15 Cytokine receptors are commonly composed of one, two or three chains. Many cytokine receptors and some cytokines, such as IL-12 p40, are members of the hematopoietin receptor superfamily of proteins. Identification of new members of the hematopoietin receptor superfamily can be useful in regulation of hematopoiesis, in regulation of immune responses and in identification of other

20 members of the hematopoietin superfamily, including cytokines and receptors.

It would be desirable to identify and determine the DNA and protein sequence for heretofore unknown members of the hematopoietin receptor superfamily.

25 Summary of the Invention

In accordance with the present invention, polynucleotides encoding the U4 hematopoietin receptor superfamily chain are disclosed, including without limitation those from the murine and human sources. In certain embodiments, the invention provides an isolated polynucleotide comprising a nucleotide sequence

30 selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:4 from nucleotide 242 to nucleotide 1396;

5 (b) the nucleotide sequence of SEQ ID NO:6 from nucleotide 71 to nucleotide 1225;

(c) a nucleotide sequence varying from the sequence of the nucleotide sequence specified in (a) or (b) as a result of degeneracy of the genetic code;

10 (d) a nucleotide sequence capable of hybridizing under stringent conditions to the nucleotide specified in (a) or (b);

(e) a nucleotide sequence encoding a species homologue of the sequence specified in (a) or (b); and

(f) an allelic variant of the nucleotide sequence specified in (a) or (b). Preferably, the nucleotide sequence encodes a protein having a biological activity of the U4 hematopoietin receptor superfamily chain. The nucleotide sequence may be operably linked to an expression control sequence. In preferred embodiments, the polynucleotide comprises the nucleotide sequence of SEQ ID NO:4 from nucleotide 242 to nucleotide 1396; the nucleotide sequence of SEQ ID NO:4 from nucleotide 122 to nucleotide 1396; the nucleotide sequence of SEQ ID NO:6 from nucleotide 71 to nucleotide 1225; or the nucleotide sequence of SEQ ID NO:6 from nucleotide 11 to nucleotide 1225.

The invention also provides isolated polynucleotides comprising a nucleotide sequence encoding a peptide or protein comprising an amino acid sequence selected from the group consisting of:

25 (a) the amino acid sequence of SEQ ID NO:5;

(b) the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425;

(c) the amino acid sequence of SEQ ID NO:7;

(d) the amino acid sequence of SEQ ID NO:7 from amino acids 24 to 30 408; and

(e) fragments of (a)-(d) having a biological activity of the U4 hematopoietin receptor superfamily chain. Other preferred embodiments encode the amino acid sequence of SEQ ID NO:5; the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425; the amino acid sequence of SEQ ID NO:7; and 35 the amino acid sequence of SEQ ID NO:7 from amino acids 24 to 408.

5 Host cells, preferably mammalian cells, transformed with the polynucleotides are also provided.

 In other embodiments, the invention provides a process for producing a U4 protein. The process comprises:

- 10 (a) growing a culture of the host cell of the present invention in a suitable culture medium; and
- (b) purifying the human U4 protein from the culture.

Proteins produced according to these methods are also provided.

 The present invention also provides for an isolated U4 protein comprising an amino acid sequence selected from the group consisting of:

- 15 (a) the amino acid sequence of SEQ ID NO:5;
- (b) the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425;
- (c) the amino acid sequence of SEQ ID NO:7;
- (d) the amino acid sequence of SEQ ID NO:7 from amino acids 24 to
- 20 408; and
- (e) fragments of (a)-(d) having a biological activity of the U4 hematopoietin receptor superfamily chain.

 Preferably the protein comprises the amino acid sequence of SEQ ID NO:5; the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425; the amino acid

25 sequence of SEQ ID NO:7; or the amino acid sequence of SEQ ID NO:7 from amino acids 24 to 408. In other preferred embodiments, the specified amino acid sequence is part of a fusion protein (with an additional amino acid sequence not derived from U4). Preferred fusion proteins comprise an antibody fragment, such as an Fc fragment.

30 Pharmaceutical compositions comprising a protein of the present invention and a pharmaceutically acceptable carrier are also provided.

 The present invention further provides for compositions comprising an antibody which specifically reacts with a protein of the present invention.

35 Detailed Description of Preferred Embodiments

5 The inventors of the present application have for the first time identified and provided polynucleotides encoding the U4 hematopoietin receptor superfamily chain (hereinafter "U4" or "U4 protein"), including without limitation polynucleotides encoding murine and human U4.

10 A 79 amino acid region of the human IL-5 receptor (LMTNAFISIDDLISKYDVQVRAAVSSMCREAGLWSEWSQPIYVGND EHKPLREWFVIVIMATICFILLIL, SEQ ID NO:1) was used to search the GenBank EST database using the TBLASTN algorithm. EST W66776 was identified with homology to this region, suggesting that this might encode a novel hematopoietin receptor. Translation of the reverse-complement of this EST using
15 the GCG map program revealed a protein sequence in the second reading frame that contained the conserved WSXWS motif found in hematopoietin receptors. However, a stop codon was also present in this reading frame at nucleotide 227, indicating that this EST either was not a novel hematopoietin receptor, or that the DNA sequence in the EST was incorrect.

20 To determine whether this EST sequence might be related to a hematopoietin receptor, we screened a murine embryo library with an oligonucleotide probe of the sequence CTTGGCTTGG AAGAGGAAAT CCTTGAGAGC (SEQ ID NO:2). A full-length cDNA clone U6-3(1A) was identified and complete sequence was obtained. The DNA sequence and the
25 predicted amino acid sequence for the murine protein are reported as SEQ ID NO:4 and SEQ ID NO:5, respectively. The murine protein encodes a novel member of the hematopoietin receptor family. It has a leader sequence, and the conserved cysteine pairs, PP, and WSXWS motifs characteristic of this family. This clone has no transmembrane or cytoplasmic domains. Alignment of this clone with the
30 EST in GenBank revealed that the EST did have a frame shift mutation.

 SEQ ID NO:4 provides the nucleotide sequence of a cDNA encoding the murine U4. SEQ ID NO:5 provides predicted the amino acid sequence of the receptor chain, including a putative signal sequence from amino acids 1-40. The mature murine U4 is believed to have the sequence of amino acids 41-383 of SEQ
35 ID NO:5.

5 To identify additional related sequences in GenBank, the W66776 sequence was used to search GenBank using the BLASTN algorithm. A closely related EST, H14009, derived from human genomic DNA was identified. An oligonucleotide derived from this EST CTGAGCGTGC GCTGGGTGTC GCCAC (SEQ ID NO:3) was then used to isolate a cDNA clone from a human cDNA library. A
10 cDNA clone (HU4-3B) encoding a full-length mature protein homolog was completely sequenced. This clone does not have a complete signal sequence, but does encode the entire predicted full-length mature protein. The human clone is 85% homologous at the DNA level with the mouse clone. The predicted amino acid sequences have 95% identity between human and mouse. The nucleotide and
15 amino acid sequence for human U4 are reported as SEQ ID NO:6 and SEQ ID NO:7, respectively.

SEQ ID NO:6 provides the nucleotide sequence of a cDNA encoding the human U4. SEQ ID NO:7 provides predicted the amino acid sequence of the receptor chain, including a putative signal sequence from amino acids 1-23. The
20 mature human U4 is believed to have the sequence of amino acids 24-380 of SEQ ID NO:7.

The murine and human clones were deposited with the American Type Culture Collection on January ___, 1997, as accession numbers ATCC _____ and ATCC _____, respectively.

25 Human U4 protein can be expressed by replacing the human leader sequence with the sequence of the murine leader, or by extending the human leader sequence with amino acids 1-14 of the murine sequence (MPAGRPGPVA QSAR, SEQ ID NO:8). Additionally, a longer cDNA or genomic clone encoding the actual human leader can be isolated using the sequences disclosed herein as probes.

30 Any forms of U4 proteins of less than full length are encompassed within the present invention and are referred to herein collectively with full length and mature forms as "U4" or "U4 proteins." U4 proteins of less than full length may be produced by expressing a corresponding fragment of the polynucleotide encoding the full-length U4 protein (SEQ ID NO:4 or SEQ ID NO:6). These
35 corresponding polynucleotide fragments are also part of the present invention.

5 Modified polynucleotides as described above may be made by standard molecular biology techniques, including construction of appropriate desired deletion mutants, site-directed mutagenesis methods or by the polymerase chain reaction using appropriate oligonucleotide primers.

10 For the purposes of the present invention, a protein has "a biological activity of the U4 hematopoietin receptor superfamily chain" if it possess one or more of the biological activities of the corresponding mature U4 protein.

U4 or active fragments thereof (U4 proteins) may be fused to carrier molecules such as immunoglobulins. For example, soluble forms of the U4 may be fused through "linker" sequences to the Fc portion of an immunoglobulin. Other fusions proteins, such as those with GST, Lex-A or MBP, may also be used.

15 The invention also encompasses allelic variants of the nucleotide sequences as set forth in SEQ ID NO:4 or SEQ ID NO:6, that is, naturally-occurring alternative forms of the isolated polynucleotide of SEQ ID NO:4 or SEQ ID NO:6 which also encode U4 proteins, preferably those proteins having a biological activity of U4. Also included in the invention are isolated polynucleotides which hybridize to the nucleotide sequence set forth in SEQ ID NO:4 or SEQ ID NO:6 under highly stringent conditions (for example, 0.1xSSC at 65°C). Isolated polynucleotides which encode U4 proteins but which differ from the nucleotide sequence set forth in SEQ ID NO:4 or SEQ ID NO:6 by virtue of the degeneracy of the genetic code are also encompassed by the present invention. Variations in the nucleotide sequence as set forth in SEQ ID NO:4 or SEQ ID NO:6 which are caused by point mutations or by induced modifications are also included in the invention.

20 The present invention also provides polynucleotides encoding homologues of the murine and human U4 from other animal species, particularly other mammalian species. Species homologues can be identified and isolated by making probes or primers from the murine or human sequences disclosed herein and screening a library from an appropriate species, such as for example libraries constructed from PBMCs, thymus or testis of the relevant species.

5 The isolated polynucleotides of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the U4 protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also
10 known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means enzymatically or chemically ligated to form a covalent bond between the isolated polynucleotide of the invention and the expression control sequence, in such a way that the U4 protein is expressed by a host cell which has been transformed (transfected) with the
15 ligated polynucleotide/expression control sequence.

 A number of types of cells may act as suitable host cells for expression of the U4 protein. Any cell type capable of expressing functional U4 protein may be used. Suitable mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal
20 A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK, Rat2, BaF3, 32D, FDCP-1, PC12, M1x or C2C12 cells.

 The U4 protein may also be produced by operably linking the isolated
25 polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and
30 Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. Soluble forms of the U4 protein may also be produced in insect cells using appropriate isolated polynucleotides as described above.

5 Alternatively, the U4 protein may be produced in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins.

10 Expression in bacteria may result in formation of inclusion bodies incorporating the recombinant protein. Thus, refolding of the recombinant protein may be required in order to produce active or more active material. Several methods for obtaining correctly folded heterologous proteins from bacterial inclusion bodies are known in the art. These methods generally involve solubilizing the protein from the inclusion bodies, then denaturing the protein completely using a chaotropic agent. When cysteine residues are present in the primary amino acid sequence of the protein, it is often necessary to accomplish the refolding in an environment which allows correct formation of disulfide bonds (a redox system). General methods of refolding are disclosed in Kohno, Meth. Enzym., 185:187-195 (1990). EP 0433225 and copending application USSN 20 08/163,877 describe other appropriate methods.

 The U4 protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, 25 or sheep which are characterized by somatic or germ cells containing a polynucleotide sequence encoding the U4 protein.

 The U4 protein of the invention may be prepared by growing a culture transformed host cells under culture conditions necessary to express the desired protein. The resulting expressed protein may then be purified from the culture medium or cell extracts. Soluble forms of the U4 protein of the invention can be 30 purified from conditioned media. Membrane-bound forms of U4 protein of the invention can be purified by preparing a total membrane fraction from the expressing cell and extracting the membranes with a non-ionic detergent such as Triton X-100.

5 The U4 protein can be purified using methods known to those skilled in the art. For example, the U4 protein of the invention can be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a purification matrix such as a gel filtration medium.

10 Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) or polyethyleneimine (PEI) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices

15 comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred (e.g., S-Sepharose® columns). The purification of the U4 protein from culture supernatant may also include one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; or by hydrophobic interaction chromatography using such resins as

20 phenyl ether, butyl ether, or propyl ether; or by immunoaffinity chromatography. Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the U4 protein. Affinity columns including antibodies to the U4 protein can also be used

25 in purification in accordance with known methods. Some or all of the foregoing purification steps, in various combinations or with other known methods, can also be employed to provide a substantially purified isolated recombinant protein. Preferably, the isolated U4 protein is purified so that it is substantially free of other mammalian proteins.

30 U4 proteins of the invention may also be used to screen for agents which are capable of binding to U4. Binding assays using a desired binding protein, immobilized or not, are well known in the art and may be used for this purpose using the U4 protein of the invention. Purified cell based or protein based (cell free) screening assays may be used to identify such agents. For example, U4

5 protein may be immobilized in purified form on a carrier and binding or potential ligands to purified U4 protein may be measured.

U4 proteins, purified from cells or recombinantly produced, may be used as a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may contain, in addition to U4 or inhibitor
10 and carrier, various diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration.

15 The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-14, IL-15, G-CSF, stem cell factor, and erythropoietin. The pharmaceutical composition may also include anti-cytokine antibodies. The pharmaceutical composition may
20 contain thrombolytic or anti-thrombotic factors such as plasminogen activator and Factor VIII. The pharmaceutical composition may further contain other anti-inflammatory agents. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with isolated U4 protein, or to minimize side effects caused by the isolated U4 protein. Conversely,
25 isolated U4 protein may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

30 The pharmaceutical composition of the invention may be in the form of a liposome in which isolated U4 protein is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers which in aqueous solution. Suitable lipids for liposomal
35 formulation include, without limitation, monoglycerides, diglycerides, sulfatides.

5 lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

10 As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, e.g., amelioration of symptoms of, healing of, or increase in rate of healing of such conditions. When applied to an individual active ingredient, administered alone, the term refers to
15 that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of isolated U4 protein is administered to a
20 mammal. Isolated U4 protein may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, U4 protein may be administered either simultaneously with
25 the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering U4 protein in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

30 Administration of U4 protein used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of U4 protein is administered
35 orally, U4 protein will be in the form of a tablet, capsule, powder, solution or elixir.

5 When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% U4 protein, and preferably from about 25 to 90% U4 protein. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral
10 oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of U4
15 protein, and preferably from about 1 to 50% U4 protein.

When a therapeutically effective amount of U4 protein is administered by intravenous, cutaneous or subcutaneous injection, U4 protein will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity,
20 stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to U4 protein an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The
25 pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additive known to those of skill in the art.

The amount of U4 protein in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated,
30 and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of U4 protein with which to treat each individual patient. Initially, the attending physician will administer low doses of U4 protein and observe the patient's response. Larger doses of U4 protein may be administered until the optimal therapeutic effect is obtained for the patient, and
35 at that point the dosage is not generally increased further. It is contemplated that

5 the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 µg to about 100 mg of U4 protein per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being
10 treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the U4 protein will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

15 The polynucleotide and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors
20 suitable for introduction of DNA).

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may
25 induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for
30 cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those
35 described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986;

- 5 Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell
10 stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

- 15 Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al.,
20 Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current
25 Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others,
30 proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and
35 their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

5 Immune Stimulating or Suppressing Activity

 A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating
10 (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present
15 invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

 Autoimmune disorders which may be treated using a protein of the present
20 invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions,
25 such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

 Using the proteins of the invention it may also be possible to modulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an
30 immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves
35 inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

5 Down regulating or preventing one or more antigen functions (including without
limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing
high level lymphokine synthesis by activated T cells, will be useful in situations of tissue,
skin and organ transplantation and in graft-versus-host disease (GVHD). For example,
10 blockage of T cell function should result in reduced tissue destruction in tissue
transplantation. Typically, in tissue transplants, rejection of the transplant is initiated
through its recognition as foreign by T cells, followed by an immune reaction that destroys
the transplant. The administration of a molecule which inhibits or blocks interaction of a
B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble,
15 monomeric form of a peptide having B7-2 activity alone or in conjunction with a
monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-
1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the
molecule to the natural ligand(s) on the immune cells without transmitting the
corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter
prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an
20 immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize
the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B
lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration
of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a
subject, it may also be necessary to block the function of a combination of B lymphocyte
25 antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection
or GVHD can be assessed using animal models that are predictive of efficacy in humans.
Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats
and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to
30 examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described
in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci
USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed.,
Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to
determine the effect of blocking B lymphocyte antigen function *in vivo* on the development
35 of that disease.

Blocking antigen function may also be therapeutically useful for treating
autoimmune diseases. Many autoimmune disorders are the result of inappropriate
activation of T cells that are reactive against self tissue and which promote the production
of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the

5 activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting
10 receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune
15 collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation
20 of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.
25

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro*
30 activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.
35

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present

5 invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or
10 in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation
15 signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an
20 MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (*e.g.*, B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of
25 an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

30 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates
35 and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA

5 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

10 Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

15 Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 20 7, *Immunologic studies in Humans*); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., *Journal of Experimental Medicine* 173:549-559, 1991; Macatonia et al., *Journal of Immunology* 154:5071-5079, 1995; Porgador et al., *Journal of Experimental Medicine* 182:255-260, 1995; Nair et al., *Journal of Virology* 67:4062-4069, 1993; Huang et al., *Science* 264:961-965, 1994; Macatonia et al., *Journal of Experimental Medicine* 169:1255-1264, 1989; Bhardwaj et al., *Journal of Clinical Investigation* 94:797-807, 1994; and Inaba et al., *Journal of Experimental Medicine* 172:631-640, 1990.

25 Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., *Cytometry* 13:795-808, 1992; Gorczyca et al., *Leukemia* 7:659-670, 1993; Gorczyca et al., *Cancer Research* 53:1945-1951, 1993; Itoh et al., *Cell* 66:233-243, 1991; Zacharchuk, *Journal of Immunology* 145:4037-4045, 1990; Zamai et al., *Cytometry* 14:891-897, 1993; Gorczyca et al., *International Journal of Oncology* 1:639-648, 1992.

5 Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

10 Hematopoiesis Regulating Activity

 A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelosuppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

 The activity of a protein of the invention may, among other means, be measured by the following methods:

 Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

 Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al.,

- 5 Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hiramaya et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Research Uses and Utilities

polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays

5 (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput
10 screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative
15 receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

20 Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F.
25 Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional
30 sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the
35 case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

U4 proteins of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the U4

5 protein and which may inhibit binding of ligands to the receptor. Such antibodies may be obtained using the entire U4 as an immunogen, or by using fragments of U4. Smaller fragments of the U4 may also be used to immunize animals. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Additional peptide immunogens may be generated by replacing tyrosine residues with sulfated tyrosine residues. Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J.Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, et al., FEBS Lett. 211, 10 (1987).

10 Neutralizing or non-neutralizing antibodies (preferably monoclonal antibodies) binding to U4 protein may also be useful therapeutics for certain tumors and also in the treatment of conditions described above. These neutralizing monoclonal antibodies may be capable of blocking ligand binding to the U4 receptor chain.

20 Example

Expression of U4 Protein

DNA encoding the full-length murine U4 protein was fused to a spacer sequence encoding Gly-Ser-Gly by PCR and ligated in frame with sequences encoding the hinge CH2 CH3 regions of human IgG1 in the COS-1 expression vector pED.Fc. The DNA was transfected into Cos cells and expression of the fusion protein was detected by ELISA using antibodies that detected the IgG1 portion of the protein. This demonstrated that the protein could be expressed and secreted in Cos cells.

30 All patent and literature references cited herein are incorporated by reference as if fully set forth.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: GENETICS INSTITUTE, INC.
- (ii) TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN
- (iii) NUMBER OF SEQUENCES: 8
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Genetics Institute, Inc.
 - (B) STREET: 87 CambridgePark Drive
 - (C) CITY: Cambridge
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02140
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Brown, Scott A.
 - (B) REGISTRATION NUMBER: 32,724
 - (C) REFERENCE/DOCKET NUMBER: GI5287-PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (617) 498-8224
 - (B) TELEFAX: (617) 876-5851

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 70 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Leu Met Thr Asn	Ala Phe Ile Ser	Ile Ile Asp Asp	Leu Ser Lys Tyr
1	5	10	15
Asp Val Gln Val	Arg Ala Ala Val	Ser Ser Met Cys	Arg Glu Ala Gly
20	25	30	
Leu Trp Ser Glu	Trp Ser Gln Pro	Ile Tyr Val Gly	Asn Asp Glu His
35	40	45	
Lys Pro Leu Arg	Glu Trp Phe Val	Ile Val Ile Met	Ala Thr Ile Cys
50	55	60	

Phe Ile Leu Leu Ile Leu
65 70

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "probe"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CTTGGCTTGG AAGAGGAAAT CCTTGAGAGC 30

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "probe"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTGAGCGTGC GCTGGGTGTC GCCAC 25

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1656 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GTGACCTTC GCTGTCCGCG CCCAGTGACG CGCGTGAGGA CCCGAGCCCC AATCTGCACC 60
 CCGCAGACTC GCCCCGCCCC CATACCGGCG TTGCAGTCAC CGCCCGTTGC GCGCCACCCC 120
 CATGCCCGCG GGTCGCCCCG GCCCCGTGCG CCAATCCGCG CGGCGGCCGC CGCGGCCCGCT 180
 GTCCTCGCTG TGGTCGCCTC TGTGCTCTG TGTCCTCGGG GTGCCTCGGG GCGGATCGGG 240
 AGCCACACA GCTGTAATCA GCCCCAGGA CCCACCTTT CTCATCGGCT CCTCCCTGCA 300
 AGCTACCTGC TCTATACATG GAGACACACC TGGGGCCACC GCTGAGGGGC TCTACTGGAC 360
 CCTCAATGGT CGCCGCCTGC CCTCTGAGCT GTCCCGCCTC CTTAACACCT CCACCCTGGC 420
 CCTGGCCCTG GCTAACCTTA ATGGGTCCAG GCAGCAGTCA GGAGACAATC TGGTGTGTCA 480

```

CGCCCGAGAT GGCAGCATTC TGGCTGGCTC CTGCCCTCTAT GTTGGCTTGC CCCCTGAGAA      540
GCCTTTTAAAC ATCAGCTGCT GGTCCCGGAA CATGAAGGAT CTCACGTGCC GCTGGACACC      600
GGGTGCACAC GGGGAGACAT TCTTACATAC CAACTACTCC CTCAAGTACA AGCTGAGGTG      660
GTACGGTCAG GATAACACAT GTGAGGAGTA CCACACTGTG GGCCCTCACT CATGCCATAT      720
CCCCAAGGAC CTGGCCCTCT TCACTCCCTA TGAGATCTGG GTGGAAGCCA CCAATCGCCT      780
AGGCTCAGCA AGATCTGATG TCCTCACACT GGATGTCCTG GACGTGGTGA CCACGGACCC      840
CCCACCCGAC GTGCACGTGA GCCGCGTTGG GGGCCTGGAG GACCAGCTGA GTGTGCGCTG      900
GGTCTCACCA CCAGCTCTCA AGGATTTCTT CTTCCAAGCC AAGTACCAGA TCCGCTACCG      960
CGTGGAGGAC AGCGTGGACT GGAAGGTGGT GGATGACGTC AGCAACCAGA CCTCCTGCCG     1020
TCTCGCGGGC CTGAAGCCCG GCACCGTTTA CTTTCGTCAA GTGCGTTGTA ACCCATTCGG     1080
GATCTATGGG TCGAAAAAGG CGGGAATCTG GAGCGAGTGG AGCCACCCCA CCGCTGCCTC     1140
CACCCCTCGA AGTGAGCGCC CGGGCCCGGG CGGCGGGGTG TGCGAGCCGC GGGGCGGCGA     1200
GCCCAGCTCG GGCCCGGTGC GGCGCGAGCT CAAGCAGTTC CTCGGCTGGC TCAAGAAGCA     1260
CGCATACTGC TCGAACCTTA GTTCCGCCT GTACGACCAG TGGCGTGCTT GGATGCAGAA     1320
GTCACACAAG ACCCGAAACC AGGACGAGGG GATCCTGCCC TCGGGCAGAC GGGGTGCGGC     1380
GAGAGGTCCT GCCGGCTAAA CTCTAAGGAT AGGCCATCCT CCTGCTGGGT CAGACCTGGA     1440
GGCTCACCTG AATTGGAGCC CCTCTGTACC ATCTGGGCAA CAAAGAAACC TACCAGAGGC     1500
TGGGGCACAA TGAGCTCCCA CAACCACAGC TTTGGTCCAC ATGATGGTCA CACTTGGATA     1560
TACCCAGTG TGGGTAGGGT TGGGGTATTG CAGGGCCTCC CAAGAGTCTC TTAAATAAA     1620
TAAAGGAGTT GTTCAGGTCC CGAAAAAAA GTCGAC                                1656

```

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 425 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Met Pro Ala Gly Arg Pro Gly Pro Val Ala Gln Ser Ala Arg Arg Pro
1           5           10           15
Pro Arg Pro Leu Ser Ser Leu Trp Ser Pro Leu Leu Leu Cys Val Leu
20           25           30
Gly Val Pro Arg Gly Gly Ser Gly Ala His Thr Ala Val Ile Ser Pro
35           40           45
Gln Asp Pro Thr Phe Leu Ile Gly Ser Ser Leu Gln Ala Thr Cys Ser
50           55           60
Ile His Gly Asp Thr Pro Gly Ala Thr Ala Glu Gly Leu Tyr Trp Thr
65           70           75           80

```

Leu Asn Gly Arg Arg Leu Pro Ser Glu Leu Ser Arg Leu Leu Asn Thr
 85 90 95
 Ser Thr Leu Ala Leu Ala Leu Ala Asn Leu Asn Gly Ser Arg Gln Gln
 100 105 110
 Ser Gly Asp Asn Leu Val Cys His Ala Arg Asp Gly Ser Ile Leu Ala
 115 120 125
 Gly Ser Cys Leu Tyr Val Gly Leu Pro Pro Glu Lys Pro Phe Asn Ile
 130 135 140
 Ser Cys Trp Ser Arg Asn Met Lys Asp Leu Thr Cys Arg Trp Thr Pro
 145 150 155 160
 Gly Ala His Gly Glu Thr Phe Leu His Thr Asn Tyr Ser Leu Lys Tyr
 165 170 175
 Lys Leu Arg Trp Tyr Gly Gln Asp Asn Thr Cys Glu Glu Tyr His Thr
 180 185 190
 Val Gly Pro His Ser Cys His Ile Pro Lys Asp Leu Ala Leu Phe Thr
 195 200 205
 Pro Tyr Glu Ile Trp Val Glu Ala Thr Asn Arg Leu Gly Ser Ala Arg
 210 215 220
 Ser Asp Val Leu Thr Leu Asp Val Leu Asp Val Val Thr Thr Asp Pro
 225 230 235 240
 Pro Pro Asp Val His Val Ser Arg Val Gly Gly Leu Glu Asp Gln Leu
 245 250 255
 Ser Val Arg Trp Val Ser Pro Pro Ala Leu Lys Asp Phe Leu Phe Gln
 260 265 270
 Ala Lys Tyr Gln Ile Arg Tyr Arg Val Glu Asp Ser Val Asp Trp Lys
 275 280 285
 Val Val Asp Asp Val Ser Asn Gln Thr Ser Cys Arg Leu Ala Gly Leu
 290 295 300
 Lys Pro Gly Thr Val Tyr Phe Val Gln Val Arg Cys Asn Pro Phe Gly
 305 310 315 320
 Ile Tyr Gly Ser Lys Lys Ala Gly Ile Trp Ser Glu Trp Ser His Pro
 325 330 335
 Thr Ala Ala Ser Thr Pro Arg Ser Glu Arg Pro Gly Pro Gly Gly Gly
 340 345 350
 Val Cys Glu Pro Arg Gly Gly Glu Pro Ser Ser Gly Pro Val Arg Arg
 355 360 365
 Glu Leu Lys Gln Phe Leu Gly Trp Leu Lys Lys His Ala Tyr Cys Ser
 370 375 380
 Asn Leu Ser Phe Arg Leu Tyr Asp Gln Trp Arg Ala Trp Met Gln Lys
 385 390 395 400
 Ser His Lys Thr Arg Asn Gln Asp Glu Gly Ile Leu Pro Ser Gly Arg
 405 410 415
 Arg Gly Ala Ala Arg Gly Pro Ala Gly
 420 425

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1579 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

GCGGCCGCCG CCGTTGCTGC CCCTGCTGCT GCTGCTCTGC GTCCTCGGGG CGCCGCGAGC   60
CGGATCAGGA GCCACACAG CTGTGATCAG TCCCCAGGAT CCCACGCTTC TCATCGGCTC   120
CTCCCTGCTG GCCACCTGCT CAGTGCACGG AGACCCACCA GGAGCCACCG CCGAGGGCCT   180
CTACTGGACC CTCAACGGGC GCCGCCTGCC CCCTGAGCTC TCCCGTGTAC TCAACGCCTC   240
CACCTTGGCT CTGGCCCTGG CCAACCTCAA TGGGTCCAGG CAGCGGTCGG GGGACAACCT   300
CGTGTGCCAC GCCCGTGACG GCAGCATCCT GGCTGGCTCC TGCCTCTATG TTGGCCTGCC   360
CCCAGAGAAA CCCGTCAACA TCAGCTGCTG GTCCAAGAAC ATGAAGGACT TGACCTGCCG   420
CTGGACGCCA GGGGCCCACG GGGAGACCTT CCTCCACACC AACTACTCCC TCAAGTACAA   480
GCTTAGGTGG TATGGCCAGG ACAACACATG TGAGGAGTAC CACACAGTGG GGCCCCACTC   540
CTGCCACATC CCAAGGACC TGGCTCTCTT TACGCCCTAT GAGATCTGGG TGGAGGCCAC   600
CAACCGCCTG GGCTCTGCCC GCTCCGATGT ACTCACGCTG GATATCCTGG ATGTGGTGAC   660
CACGGACCCC CCGCCCGACG TGCACGTGAG CCGCGTCGGG GGCCTGGAGG ACCAGCTGAG   720
CGTGCCTGG GTGTCGCCAC CCGCCCTCAA GGATTTCTCT TTTCAAGCCA AATACCAGAT   780
CCGCTACCGA GTGGAGGACA GTGTGGACTG GAAGGTGGTG GACGATGTGA GCAACCAGAC   840
CTCCTGCCGC CTGGCCGGCC TGAAACCCGG CACCGTGTAC TTCGTGCAAG TGCCTGCAA   900
CCCCTTTGGC ATCTATGGCT CCAAGAAAGC CGGGATCTGG AGTGAGTGGA GCCACCCAC   960
AGCCGCCTCC ACTCCCCGCA GTGAGCGCCC GGGCCCGGGC GCGGGGCGT GCGAACC GCG   1020
GGGCGGAGAG CCGAGCTCGG GGCCGGTGCG GCGCGAGCTC AAGCAGTTCC TGGGCTGGCT   1080
CAAGAAGCAC GCGTACTGCT CCAACCTCAG CTTCGCCTC TACGACCAGT GGCGAGCCTG   1140
GATGCAGAAG TCGCACAAGA CCCGCAACCA GGACGAGGGG ATCCTGCCCT CGGGCAGACG   1200
GGGCACGGCG AGAGGTCTG CCAGATAAGC TGTAGGGGCT CAGGCCACCC TCCCTGCCAC   1260
GTGGAGACGC AGAGGCCGAA CCCAACTGG GGCCACCTCT GTACCCCTCAC TTCAGGGCAC   1320
CTGAGCCACC CTCAGCAGGA GCTGGGGTGG CCCCTGAGCT CCAACGGCCA TAACAGCTCT   1380
GACTCCACG TGAGGCCACC TTTGGGTGCA CCCAGTGGG TGTGTGTGTG TGTGTGAGGG   1440
TTGGTTGAGT TGCCTAGAAC CCCTGCCAGG GCTGGGGGTG AGAAGGGGAG TCATTACTCC   1500
CCATTACCTA GGGCCCTCC AAAAGAGTCC TTTTAAATAA ATGAGCTATT TAGGTGCTGT   1560
GAAAAAAAAA AAAAAAAAAA                                     1579

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 408 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Arg Pro Pro Pro Leu Leu Pro Leu Leu Leu Leu Cys Val Leu Gly
1          5          10          15
Ala Pro Arg Ala Gly Ser Gly Ala His Thr Ala Val Ile Ser Pro Gln
20          25          30
Asp Pro Thr Leu Leu Ile Gly Ser Ser Leu Leu Ala Thr Cys Ser Val
35          40          45
His Gly Asp Pro Pro Gly Ala Thr Ala Glu Gly Leu Tyr Trp Thr Leu
50          55          60
Asn Gly Arg Arg Leu Pro Pro Glu Leu Ser Arg Val Leu Asn Ala Ser
65          70          75          80
Thr Leu Ala Leu Ala Leu Ala Asn Leu Asn Gly Ser Arg Gln Arg Ser
85          90          95
Gly Asp Asn Leu Val Cys His Ala Arg Asp Gly Ser Ile Leu Ala Gly
100         105         110
Ser Cys Leu Tyr Val Gly Leu Pro Pro Glu Lys Pro Val Asn Ile Ser
115        120        125
Cys Trp Ser Lys Asn Met Lys Asp Leu Thr Cys Arg Trp Thr Pro Gly
130        135        140
Ala His Gly Glu Thr Phe Leu His Thr Asn Tyr Ser Leu Lys Tyr Lys
145        150        155        160
Leu Arg Trp Tyr Gly Gln Asp Asn Thr Cys Glu Glu Tyr His Thr Val
165        170        175
Gly Pro His Ser Cys His Ile Pro Lys Asp Leu Ala Leu Phe Thr Pro
180        185        190
Tyr Glu Ile Trp Val Glu Ala Thr Asn Arg Leu Gly Ser Ala Arg Ser
195        200        205
Asp Val Leu Thr Leu Asp Ile Leu Asp Val Val Thr Thr Asp Pro Pro
210        215        220
Pro Asp Val His Val Ser Arg Val Gly Gly Leu Glu Asp Gln Leu Ser
225        230        235        240
Val Arg Trp Val Ser Pro Pro Ala Leu Lys Asp Phe Leu Phe Gln Ala
245        250        255
Lys Tyr Gln Ile Arg Tyr Arg Val Glu Asp Ser Val Asp Trp Lys Val
260        265        270
Val Asp Asp Val Ser Asn Gln Thr Ser Cys Arg Leu Ala Gly Leu Lys
275        280        285
Pro Gly Thr Val Tyr Phe Val Gln Val Arg Cys Asn Pro Phe Gly Ile
290        295        300

```

Tyr Gly Ser Lys Lys Ala Gly Ile Trp Ser Glu Trp Ser His Pro Thr
 305 310 315 320
 Ala Ala Ser Thr Pro Arg Ser Glu Arg Pro Gly Pro Gly Gly Gly Ala
 325 330 335
 Cys Glu Pro Arg Gly Gly Glu Pro Ser Ser Gly Pro Val Arg Arg Glu
 340 345 350
 Leu Lys Gln Phe Leu Gly Trp Leu Lys Lys His Ala Tyr Cys Ser Asn
 355 360 365
 Leu Ser Phe Arg Leu Tyr Asp Gln Trp Arg Ala Trp Met Gln Lys Ser
 370 375 380
 His Lys Thr Arg Asn Gln Asp Glu Gly Ile Leu Pro Ser Gly Arg Arg
 385 390 395 400
 Gly Thr Ala Arg Gly Pro Ala Arg
 405

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Pro Ala Gly Arg Pro Gly Pro Val Ala Asn Ser Ala Arg
 1 5 10

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:4 from nucleotide 242 to nucleotide 1396;

(b) the nucleotide sequence of SEQ ID NO:6 from nucleotide 71 to nucleotide 1225;

(c) a nucleotide sequence varying from the sequence of the nucleotide sequence specified in (a) or (b) as a result of degeneracy of the genetic code;

(d) a nucleotide sequence capable of hybridizing under stringent conditions to the nucleotide specified in (a) or (b);

(e) a nucleotide sequence encoding a species homologue of the sequence specified in (a) or (b); and

(f) an allelic variant of the nucleotide sequence specified in (a) or (b).

2. The polynucleotide of claim 1 wherein said nucleotide sequence encodes for a protein having a biological activity of the U4 hematopoietin receptor superfamily chain.

3. The polynucleotide of claim 1 wherein said nucleotide sequence is operably linked to an expression control sequence.

4. The polynucleotide of claim 1 comprising the nucleotide sequence of SEQ ID NO:4 from nucleotide 122 to nucleotide 1396.

5. The polynucleotide of claim 1 comprising the nucleotide sequence of SEQ ID NO:6, from nucleotide 11 to nucleotide 1225.

6. A host cell transformed with the polynucleotide of claim 3.

7. The host cell of claim 6, wherein said cell is a mammalian cell.

8. A process for producing a U4 protein, said process comprising:

- (a) growing a culture of the host cell of claim 6 in a suitable culture medium; and
- (b) purifying the U4 protein from the culture.

9. An isolated U4 protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:5;
- (b) the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425;
- (c) the amino acid sequence of SEQ ID NO:7;
- (d) the amino acid sequence of SEQ ID NO:7 from amino acids 24 to 408; and
- (e) fragments of (a)-(d) having a biological activity of the U4 hematopoietin receptor superfamily chain.

10. The protein of claim 9 comprising the amino acid sequence of SEQ ID NO:5.

11. The protein of claim 9 comprising the sequence from amino acid 41 to 425 of SEQ ID NO:5.

12. The protein of claim 9 comprising the amino acid sequence of SEQ ID NO:7.
13. The protein of claim 9 comprising the sequence from amino acid 24 to 408 of SEQ ID NO:7.
14. A pharmaceutical composition comprising a protein of claim 9 and a pharmaceutically acceptable carrier.
15. A protein produced according to the process of claim 8.
16. A composition comprising an antibody which specifically reacts with a protein of claim 9.
17. An isolated polynucleotide comprising a nucleotide sequence encoding a peptide or protein comprising an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:5;
 - (b) the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425;
 - (c) the amino acid sequence of SEQ ID NO:7;
 - (d) the amino acid sequence of SEQ ID NO:7 from amino acids 24 to 408; and
 - (e) fragments of (a)-(d) having a biological activity of the U4 hematopoietin receptor superfamily chain.
18. The protein of claim 9 wherein said amino acid sequence is part of a fusion protein.
19. The protein of claim 18 comprising an Fc fragment.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/00334

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/19 C07K14/715 A61K38/17 C07K16/18 C12N15/62

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARRA M ET AL.: "AC: AA049280. Mus musculus cDNA clone 479043 5' end similar to SW: IL6B_MOUSE Q00560 interleukin-6 receptor beta chain precursor." EMBL SEQUENCE DATABASE, 31 December 1996, HEIDELBERG, GERMANY, XP002062032 see the whole document	1,3,6-8, 15
X	MARRA M ET AL.: "AC: W66776. Mus musculus cDNA clone 387741 5' end similar to PIR:B38252 granulocyte colony-stimulating factor receptor precursor." EMBL SEQUENCE DATABASE, 15 June 1996, HEIDELBERG, GERMANY, XP002062033 cited in the application see the whole document	1,3,6-8, 15
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

16 April 1998

Date of mailing of the international search report

29/04/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/00334

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LI Q Y: "AC: H14009. EST00035 Homo sapiens genomic clone D2-17 5'." EMBL SEQUENCE DATABASE, 3 July 1995, HEIDELBERG, GERMANY, XP002062036 cited in the application see the whole document</p> <p style="text-align: center;">---</p>	1,3,6-8, 15
X	<p>HILLIER L ET AL.: "AC: W46604. Homo sapiens cDNA clone 324067 3'." EMBL SEQUENCE DATABASE, 28 May 1996, HEIDELBERG, GERMANY, XP002062037 see the whole document</p> <p style="text-align: center;">---</p>	1,3,6-8, 15
A	<p>WO 96 08510 A (PROGENITOR INC) 21 March 1996 see abstract; figure 1; example 6 see page 2, line 32 - page 3, line 30</p> <p style="text-align: center;">---</p>	
E	<p>WO 98 11225 A (NICOLA NICOS ANTONY ;FABRI LOUIS (AU); FARLEY ALISON (AU); NASH AN) 19 March 1998 see the whole document</p> <p style="text-align: center;">-----</p>	1,3,6-8, 15

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 98/00334

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9608510 A	21-03-96	US 5643748 A AU 3419495 A CA 2176463 A EP 0730606 A	01-07-97 29-03-96 21-03-96 11-09-96
WO 9811225 A	19-03-98	NONE	